Ageing: Sildenafil as a candidate drug for Alzheimer's disease
A paper reporting that the prescription of sildenafil, a drug used to treat pulmonary hypertension and erectile dysfunction, is associated with a significant reduction in the risk of developing Alzheimer's disease is published in Nature Aging.Our findings suggest that sildenafil reperpassing may be a treatment option for Alzheimer's disease.
Alzheimer's disease (AD) is the most common form of age-related dementia, with tens of millions of patients worldwide.At present, there is no effective treatment for AD, which increases the financial burden and disease burden of society as the population ages.
Now, Feixiong Cheng and colleagues have integrated genetic and other biological data into 13 disease "endophenotype modules" that capture the biological characteristics of AD by computer-aided methods.These modules were mapped on a large network of 35 human protein-protein interactions.Network accessibility scores were then generated for over 1444 FDA-approved drugs.Drugs with a high score mean that they physically interact with multiple molecular targets within AD-related modules.Sildenafil scores are in the top group, suggesting that they may affect AD.To test this, Cheng and colleagues analyzed claims data from more than 1600 million people in the United States and found that sildenafil prescriptions significantly reduced the risk of diagnosing AD by 700% after 6 years of follow-up. It became clear that it was related to.Gender is especially important because sildenafil is primarily used to treat erectile dysfunction in men, although corrections for potentially influential factors (gender, race, age, etc.) were made in this association. ..
Cheng et al. Note that this study design cannot demonstrate a causal link between the use of a particular drug and the risk of AD.Therefore, a randomized, placebo-controlled clinical trial in both male and female subjects is needed to determine the efficacy of sildenafil in this situation.
[Original English »]
"Highlights of Nature Magazines" is a translation of a release made by Nature's public relations department for the press.If you need more accurate and detailed information, be sure to read the original paper.
* This article is reprinted from "Nature Japan Featured Highlights".
Reprinted from: "Aging: Sildenafil as a candidate for treatment of Alzheimer's disease'
